(NASDAQ: GLMD) Galmed Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Galmed Pharmaceuticals's earnings in 2026 is -$11,115,000.On average, 3 Wall Street analysts forecast GLMD's earnings for 2026 to be -$10,501,369, with the lowest GLMD earnings forecast at -$10,089,551, and the highest GLMD earnings forecast at -$10,810,233. On average, 3 Wall Street analysts forecast GLMD's earnings for 2027 to be -$6,058,482, with the lowest GLMD earnings forecast at -$5,820,895, and the highest GLMD earnings forecast at -$6,236,673.
In 2028, GLMD is forecast to generate -$5,116,052 in earnings, with the lowest earnings forecast at -$4,915,422 and the highest earnings forecast at -$5,266,524.